Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer

Clinical Cancer Research

Volumn 5, Issue 11, 1999, Pages 3460-3467

  Chan, Christina M W ^a   Lykkesfeldt, Anne E ^b   Parker, Malcolm G ^c   Dowsett, Mitchell ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; ESTRADIOL; MESSENGER RNA; NUCLEAR PROTEIN; NUCLEAR PROTEIN P140; NUCLEAR PROTEIN SUG1; NUCLEAR PROTEIN TIF1; REPRESSOR PROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REPRESSOR GENE; TRANSCRIPTION REGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARRIER PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NUCLEAR PROTEINS; POSTMENOPAUSE; PREMENOPAUSE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, ESTROGEN; RNA, MESSENGER; TAMOXIFEN; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0032711016     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Saez, R. A., and Osbome, C. K. In: B. J. Kennedy (ed.), Current Clinical Oncology, pp. 163-172. New York: Alan R. Liss, Inc., 1989.
2. Encarnacion, C. A., Ciocca, D. R., McGuire, W. L., Clark, G. M., Fuqua, S. A. W., and Osborne, C. K. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treat., 26: 237-246, 1993.
3. Johnston, S. R. D., Saccani-Jotti, G., Smith, I. E., Salter, J., Newby, J., Coppen, M., Ebbs, S. R., and Dowsett, M. Changes in estrogen-receptor, progesterone-receptor, and pS2 expression in tamoxifen-resistant human breast-cancer. Cancer Res., 55: 3331-3338, 1995.
4. Gottardis, M. M., Robinson, S. P., and Jordan, V. C. Estradiol stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J. Steroid Biochem., 30: 311-314, 1988.
5. Gottardis, M. M., and Jordan, V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res., 48: 5183-5187, 1988.
6. Howell, A., Dodwell, D. J., Laidlaw, I., Anderson, H., and Anderson, E. In: Goldhirsch, A. (ed.), Endocrine Therapy of Breast Cancer, pp. 49-58. New York: Springer-Verlag, 1990.
7. Baniahmad, A., Ha, I., Reinberg, D., Tsai, S., Tsai, M-J., and O'Malley, B. W. Interaction of human thyroid-hormone receptor-β with transcription factor TFIIB may mediate target gene depression and activation by thyroid-hormone. Proc. Natl. Acad. Sci. USA, 90: 8832-8836, 1993.
8. Ing, N. H., Beekman, J. M., Tsai, S., Tsai, M-J., and O'Malley, B. W. Members of the steroid-hormone receptor superfamily interact with TFIIB (S300-II). J. Biol. Chem., 267: 17617-17623, 1992.
9. Jacq, X., Brou, C., Lutz, Y., Davidson, I., Chambon, P., and Tora, L. Human TAF(II)30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen-receptor. Cell, 79: 107-117, 1994.
10. Tora, L., White, J., Brou, C., Tasset, D., Webster, N., Scheer, E., and Chambon, P. The human estrogen-receptor has 2 independent nonacidic transcriptional activation functions. Cell, 59: 477-487, 1989.
11. Berry, M., Metzger, P., and Chambon, P. Role of the 2 activating domains of the estrogen-receptor in the cell-type and promotor-context dependent agonistic activity of the antiestrogen 4-hydroxytamoxifen. EMBO J., 9: 2811-2818, 1990.
12. Kumar, V., and Chambon, P. The estrogen-receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell, 55: 145-146, 1988.
13. Lees, J. A., Fawell, S. E., and Parker, M. G. Identification of two transactivation domains in the mouse estrogen-receptor. Nucleic Acids Res., 17: 145477-145488, 1989.
14. Brzozowski, A. M., Pike, A. C., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Ohman, L., Greene, G. L., Gustafsson, J. A., and Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (Lond.), 389: 753-758, 1997.
15. Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A, and Greene, G. L. The structural basis of estrogen receptor/ coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 95: 927-937, 1998.
16. Horwitz, K. B., Jackson, T. A., Bain, D. L., Richer, J. K., Takimoto, G. S., and Tung, L. Nuclear receptor coactivators and corepressors. Mol. Endocrinol., 10: 1167-1177, 1996.
17. Halachmi, S., Marden, E., Martin, G., MacKay, H., Abbondanza, C., and Brown, M. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science (Washington DC), 264: 1455-1458, 1994.
18. Cavaillès, V., Dauvois, S., Danielian, P. S., and Parker, M. G. Interaction of proteins with transcriptionally active estrogen-receptor. Proc. Natl. Acad. Sci. USA, 91: 10009-10013, 1994.
19. vom Baur, E., Zechel, C., Heery, D., Heine, M. J. S., Garnier, J. M., Vivat, V., Le Douarin, B., Gronemeyer, H., Chambon, P., and Losson, R. Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J., 15: 110-124, 1996.
20. Li, H., Gomes, P. J., and Chen, J. D. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC1 and TIF2. Proc. Natl. Acad. Sci. USA, 94: 8479-8484, 1997.
21. Chen D. J, and Li, H. Coactivation and corepression in transcriptional regulation by steroid/nuclear hormone receptors. Crit. Rev. Eukaryotic Gene Expression, 8: 169-190, 1998.
22. Onate, S. A., Tsai S. Y., Tsai, M-J., and O'Malley, B. W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science (Washington DC), 270: 1354-1357, 1995.
23. Voegel, J. J., Heine, M. J. S., Zechel, C., Chambon, P., and Gronemeyer, H. TIF2, a 160kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J., 75: 3667-3675, 1996.
24. Hong, H., Kohli, K., Garabedian, M. J., and Stallcup, M. R. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Proc. Natl. Acad. Sci. USA, 93: 4948-4952, 1996.
25. Cavailles, V., Dauvois, S., L'Horset, F., Lopez, G., Hoare, S., Kushner, P. J., and Parker, M. G. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J., 14: 3741-3751, 1995.
26. LeDouarin, B., Zechel, C., Garnier, J-M., Lutz, Y., Tora, L., Pierrat, B., Heery, D., Gronemeyer, H., Chambon, P., and Losson, R. The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in oncogenic protein T18. EMBO J., 14: 2020-2033, 1995.
27. LeDouarin, B., Nielson, A. L., Garnier, J-M., Ichinose, H., Jeanmougin, F., Losson, R., and Chambon, P. A possible involvement of TIF1 α and TIF1 β in the epigenetic control of transcription by nuclear receptors. EMBO J., 15: 6701-6715, 1996.
28. Horlein, A. J., Naar, A. M., Heinzel, T., Torchia, J., Gloss, B., Kurokawa, R., Ryan, A., Kamei, Y., Soderstrom, M., Glass, C. K., and Rosenfeld, M. G. Ligand-dependent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature (Lond.), 377: 397-404, 1995.
29. Chen, D. J., and Evans, R. M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature (Lond.), 377: 454-457, 1995.
30. Xu, J., Qui, Y., deMayo, F. J., Tsai, S. Y., Tsai, M-J., and O'Malley, B. Partial hormone resistance in mice with disruption of the steroid receptor coactivator (SRC-1) gene. Science (Washington DC), 279: 1922-1925, 1998.
31. Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X-Y., Sauter, G., Kallioniemi, O-P., Treant, J. M., and Meltzer, P. S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (Washington DC), 277: 965-968, 1997.
32. Smith, L. C., Nawaz, Z., and O'Malley, B. W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol., 11: 657-666, 1997.
33. Berns, E. M. J. J., van Staveren, I. L., Klijn, J. G. M., and Foekens, J. A. Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer. Breast Cancer Res. Treat., 48: 87-92, 1998.
34. Henttu, P. M. A., Kalkhoven, E., and Parker, M. G. AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors. Mol. Cell. Biol., 17: 1832-1839, 1997.
35. Daffada, A. I. I., Johnston, S. R. D., Smith, I. E., Detre, S., King, N., and Dowsett, M. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res., 55: 288-293, 1995.
36. Briand, P., and Lykkesfeldt, A. E. Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration. Cancer Res., 44: 1114-1119, 1984.
37. Lykkesfeldt, A. E., Madsen, M. W., and Briand, P. Altered expression of estrogen regulated genes in a tamoxifen-resistant and ICI 164384 and ICI 182780 sensitive human breast cancer cell line, MCF-7/TAM-1. Cancer Res., 54: 1587-1595, 1994.
38. Katzenellenbogen, B. S., Montano, M. M., Ekena, K., Herman, M. E., and McInernery, E. M. Antiestrogens: mechanism of action and resistance in breast cancer. Breast Cancer Res. Treat., 44: 23-38, 1997.
39. Jackson, T. A., Richer, J. K., Bain, D. L., Takimoto, G. S., Tung, L., and Horwitz, K. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol., 11: 693-705, 1997.
40. Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T-M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., Hilsenbeck, S. G., Osborne, C. K., Glass, C. K., Rosenfeld, M. G., and Rose, D. W. Diverse signalling pathways modulate nuclear receptor recuitment of N-CoR and SMRT complexes. Proc. Natl. Acad. Sci. USA, 95: 2920-2925, 1998.
41. Pollack, M., Constantino, J., Polychronajas, C., Blauer, S. A., Guyda, H., Redmond, C., Fisher, B., and Margolese, R. Effects of tamoxifen on serum insulin-like growth factor levels in stage I breast cancer patients. J. Natl. Cancer Inst , 82: 1693-1697, 1990.